Svetlana Mojsov, Ph.D., was a key part of the team that discovered the function of the hormone glucagon-like peptide 1 (GLP-1) and its role in diabetes and weight loss.
Svetlana Mojsov, Ph.D., is a researcher who, early in her career, was influential part of the team of researchers at Massachusetts General Hospital who discovered the function of the hormone glucagon-like peptide 1 (GLP-1) and its role in diabetes and weight loss. Their work and the paper, where she was lead author, eventually led to the development of the blockbuster drugs Victoza, Ozempic and Mounjaro.
But somewhere along the way, Mojsov’s role had been minimized and she didn’t receive awards and recognition that that her colleagues did and was even left off several patents on the research. Several recent articles are working to correct the record, including one in Science and on Stat.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
Diabetes Management & Telehealth with Leslie Kolb
June 11th 2020Association of Diabetes Care and Education Specialists, chief science and practice officer, Leslie Kolb chats with MHE Associate Editor Briana Contreras in MHE's newest podcast Tuning into the C-Suite about diabetes management and how it's affected by the use of telehealth, especially during the current and trying times of the COVID-19 pandemic.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More